Concerns over US clinical trials as it is revealed only 41% of results are reported in accordance with new laws

Richard Tadd Industry News

In January 2017, the US passed new regulations to ensure that all clinical trials would have their results reported within one year of primary completion – with hefty fines of up to US$10,000 a day for those who failed to comply with the new rules. Despite this, a recent study published by The Lancet found that almost six in 10 …

‘Bureaucracy’ is one of the greatest threats to clinical research

Richard Tadd Industry News

In 2013, Christina Reith, fellow of The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, lead authored a paper that addressed in no uncertain terms what effect red tape was having on clinical trials in Europe. Her conclusions were damning – that for academics engaged in carrying out randomised control trials, the most pressing of issues were those …

Amgen finalises investment as Chinese biopharmaceuticals seem a strong prospect in 2020

Richard Tadd Industry News

The California-based multinational giant Amgen recently finalised an investment of $2.8 billion in Chinese pharmaceuticals, and it seems that the trends of the 2010s will continue as China continues to assert itself as a major player in the global biotechnology and pharmaceutical trades. Amgen itself has aggressively expanded its global influence since 2011, doubling its geographic presence from around 50 …